Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 17/20 | 0.56 |
| ▸ | MTOR | P42345 | 4/20 | 0.54 |
| ▸ | PIK3R1 | P27986 | 8/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26072386 | 0.94 | PIK3CA (0.56) | PIK3CAMTORPIK3R1PIK3CD | |
| SCHEMBL30366721 | 0.82 | PIK3CA (0.56) | PIK3CAMTORPIK3R1PIK3CDALDH1A1 | |
| SCHEMBL5560237 | 0.80 | PIK3CA (0.64) | PIK3CAMTORPIK3R1PIK3CDLMNA | |
| SCHEMBL26072359 | 0.79 | PIK3CA (0.50) | PIK3CAMTORPIK3R1PIK3CD | |
| SCHEMBL10092229 | 0.78 | PIK3CA (0.49) | PIK3CAMTORPIK3R1PIK3CD | |
| Lithium Ion SCHEMBL30366465 | 0.77 | PIK3CA (0.48) | PIK3CAMTORPIK3R1PIK3CD | |
| SCHEMBL26072211 | 0.74 | PIK3CA (0.44) | PIK3CAMTORPIK3R1ALDH1A1GLA | |
| SCHEMBL26072083 | 0.74 | PIK3CA (0.47) | PIK3CAMTORPIK3R1PIK3CDALDH1A1 | |
| SCHEMBL30366717 | 0.73 | PIK3CA (0.44) | PIK3CAMTORPIK3R1PIK3CD | |
| SCHEMBL13896920 | 0.73 | PIK3CA (0.45) | PIK3CAMTORPIK3R1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312577-A1 | DUAL KINASE-BROMODOMAIN INHIBITORS | MONASH UNIVERSITY (AU) | 2023-10-05 | — | — | US | disclosed |
| US-20230312577-A1 | DUAL KINASE-BROMODOMAIN INHIBITORS | MONASH UNIVERSITY (AU) | 2023-10-05 | — | — | US | disclosed |
| EP-4165045-A1 | DUAL KINASE-BROMODOMAIN INHIBITORS | Monash University (AU) | 2023-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312577-A1 | DUAL KINASE-BROMODOMAIN INHIBITORS | MAP2K2, BRPF3, BRDT | PIK3CA 574/4885MTOR 679/4885PIK3R1 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.